Logo

Section 32: Steven Kafka

Nov 05, 2019

Former Foundation Medicine President and COO Steven Kafka has joined venture capital fund Section 32 as a managing partner. He is currently executive chairman at Thrive Earlier Detection and at ArcherDX and will continue in these roles. He joins Section 32 from Third Rock Ventures, where he was a partner and venture partner and which he joined after leaving Foundation Medicine. Prior to that, he worked at Aileron Therapeutics, Infinity Pharmaceuticals, Millennium Pharmaceuticals, Strategic Decisions Group, and Forrester Research. Kafka holds a PhD in political economy and government from Harvard University and an AB in economics and political science from Stanford University. At Section 32, he joins managing partner Michael Pellini, the former CEO of Foundation Medicine.

Breaking News
The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.